Answers are grounded in this paper and cite their sources.
The hepatitis B virus (HBV) infection rate has been effectively reduced by universal vaccination. Concentrations of vaccine-induced neutralizing antibodies (anti-HBs) above 10 mIU/ml are generally regarded as sufficient for protection against HBV infection (4). The detection of the hepatitis B surface antigen (HBsAg) by enzyme immunoassay (EIA) utilizes either polyclonal and/or monoclonal anti-HBs and targets the major “a” determinant of HBsAg, although other targets may also be available for detection. Such assays may be unable to detect HBsAg “a” determinant mutants (2, 5, 6).
No takes yet. Share an insight, caveat, or question.
Chen et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: